Aclaris Therapeutics Announces Poster Presentations at 2018 American Society for Dermatologic Surgery Annual Meeting and Fall...
October 03 2018 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company focused on identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology and immunology, today
announced poster presentations at the 2018 American Society for
Dermatologic Surgery Annual Meeting in Phoenix, Arizona and the
Fall Clinical Dermatology Conference in Las Vegas, Nevada. One
poster is related to ESKATA® (hydrogen peroxide) topical solution,
40% (w/w), formerly known as “A-101,” and two posters examine the
impact of seborrheic keratoses (SKs) on patients and the need to
improve communication between dermatologists/HCPs on SK treatment
options.
- The Hidden Impact of Seborrheic
Keratoses: Analysis of a Psychometric Survey of an
Ethnically-Diverse Cohort of U.S. Adults
- Authors: S. Xu, S. Wang and E.
Estes
- Presented at the 2018 American Society
for Dermatologic Surgery Annual Meeting and Fall Clinical
Dermatology Conference
- An Open-Label Study of the Safety of
HP40, a 40% (w/w) Hydrogen Peroxide Topical Solution, in Patients
with Seborrheic Keratoses
- Authors: V. Callender, E. Frankel, J.
Weiss, W. Werschler, C. Powala, B. Beger, E. Estes and S.
Shanler
- Presented at the 2018 Fall Clinical
Dermatology Conference
- Assessing Patient Concerns Regarding
Seborrheic Keratoses on the Face: Comparison Against Other Cosmetic
Concerns
- Authors: S. Xu and S. Wang
- Presented at the 2018 Fall Clinical
Dermatology Conference
About ESKATA®ESKATA (hydrogen peroxide) topical
solution, 40% (w/w), is the first and only FDA-approved medication
for the treatment of raised seborrheic keratosis (SKs).
Important Safety Information and Approved
Use
ESKATA can cause serious side effects,
including:
- Eye problems. Eye problems can happen if
ESKATA® (hydrogen peroxide) topical solution, 40% (w/w) gets into
your eyes, including: ulcers or small holes in your eyes, scarring,
redness, irritation, eyelid swelling, severe eye pain, and
permanent eye injury, including blindness.
- If ESKATA accidentally gets into your eyes, your
healthcare provider will tell you to flush them well with water for
15 to 30 minutes. Your healthcare provider
may send you to another healthcare provider if
needed.
- Local skin reactions. Skin reactions have
happened in and around the treatment area after application of
ESKATA. Severe skin reactions can include: breakdown of the outer
layer of the skin (erosion), ulcers, blisters and scarring. Tell
your healthcare provider if you have any skin reactions during
treatment with ESKATA.
The most common side effects of ESKATA
include: itching, stinging, crusting, swelling, redness
and scaling.
Your healthcare provider will not apply another treatment of
ESKATA if your treated area is still irritated from the previous
treatment.
Tell your healthcare provider right away if ESKATA gets into
your eyes, mouth or nose during application. ESKATA is for topical
use on the skin only, and is not for use in your eyes, mouth or
vagina.
These are not all the possible side effects of ESKATA.
Approved Use for ESKATA
ESKATA is a prescription medicine used to treat seborrheic
keratoses that are raised.
ESKATA is for use as an in-office treatment. ESKATA is applied
by your healthcare provider and is not for use at home.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Contact Aclaris Therapeutics, Inc.
at 1-833-ACLARIS or 1-833-225-2747 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
About Seborrheic Keratoses
Seborrheic keratoses (SKs) are non-cancerous skin growths that
are most commonly seen in middle-aged and older adults. SKs vary in
color from flesh-colored to pink, yellow, gray, tan, brown, or
black; can range in size from a millimeter to a few centimeters
wide; and typically have a slightly elevated, waxy or scaly
appearance. The number of SKs tends to increase with advancing age.
SKs frequently appear in highly visible locations, such as the face
or neck, but can also appear anywhere on the body, except the
palms, soles and mucous membranes.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company committed to identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in dermatology, both aesthetic and medical, and immunology.
Aclaris’ focus on market segments with no FDA-approved medications
or where treatment gaps exist has resulted in the first
FDA-approved treatment for raised SKs and several clinical programs
to develop medications for the potential treatment of common warts,
alopecia areata, and vitiligo. For additional information, please
visit www.aclaristx.com and follow Aclaris on LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe”, “expect”, “may”, “plan,” “potential,” “will,” and
similar expressions, and are based on Aclaris’ current beliefs and
expectations. These forward-looking statements include expectations
regarding Aclaris’ commercialization of ESKATA and its ability to
clear raised SKs with a low risk of scarring. These statements
involve risks and uncertainties that could cause actual results to
differ materially from those reflected in such statements. Risks
and uncertainties that may cause actual results to differ
materially Aclaris’ reliance on third parties over which it may not
always have full control, risks associated with maintaining its
intellectual property portfolio and other risks and uncertainties
that are described in Aclaris’ Annual Report on Form 10-K for the
year ended December 31, 2017 and other filings Aclaris makes with
the SEC from time to time. These documents are available under the
“Financial Reporting” section of the Investors page of Aclaris’
website at http://www.aclaristx.com. Any forward-looking statements
speak only as of the date of this press release and are based on
information available to Aclaris as of the date of this release,
and Aclaris assumes no obligation to, and does not intend to,
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contacts: Aclaris Contact Michael Tung, M.D. Senior Vice
President Corporate Strategy/Investor Relations
484-329-2140mtung@aclaristx.com
Media Contact Sara Baker Marina Maher Communications
212-485-6836 sbaker@hellommc.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Sep 2023 to Sep 2024